Literature DB >> 7679003

2-Chlorodeoxyadenosine for multiple myeloma.

R Niesvizky, D Siegel, J Michaeli.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 7679003

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  4 in total

Review 1.  Cladribine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies.

Authors:  H M Bryson; E M Sorkin
Journal:  Drugs       Date:  1993-11       Impact factor: 9.546

Review 2.  Clinical and toxicological aspects of the antineoplastic drug cladribine: a review.

Authors:  H J Guchelaar; D J Richel; M R Schaafsma
Journal:  Ann Hematol       Date:  1994-11       Impact factor: 3.673

3.  Cladribine and bendamustine exhibit inhibitory activity in dexamethasone-sensitive and -resistant multiple myeloma cells.

Authors:  Bo Cai; Shuiliang Wang; Jingcao Huang; Choon-Kee Lee; Chunji Gao; Bolin Liu
Journal:  Am J Transl Res       Date:  2013-01-21       Impact factor: 4.060

4.  Therapeutic potential of cladribine in combination with STAT3 inhibitor against multiple myeloma.

Authors:  Jian Ma; Shuiliang Wang; Ming Zhao; Xin-Sheng Deng; Choon-Kee Lee; Xiao-Dan Yu; Bolin Liu
Journal:  BMC Cancer       Date:  2011-06-16       Impact factor: 4.430
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.